Aurobindo Pharma received an advisory letter from NSE under SEBI (LODR) Regulations, 2015, regarding the delay in completion of acquisition of 51% stake in GLS Pharma Limited as disclosed on June 18, 2022, and is advised to file an update in case of any delay in proposed transactions disclosed to the stock exchanges and to place the advisory letter before its Board of Directors in the ensuing Board Meeting.